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1. Introduction
  Herpes zoster (HZ) virus usually causes chickenpox 
in childhood. HZ is a common viral infection of the 
nervous system. HZ occurs in up to 20% of people 
infected with varicella-zoster virus. HZ rarely occurs 
in healthy children, but may occur frequently and 
may take a complicated course in children receiving 
chemotherapy[1]. The characteristic feature of all 
herpes viruses is that the virus stays latent or dormant 
in the sensory root ganglia and then reactivates to 
produce recurrent diseases[1]. 
   During the latent period, the virus infects both 
neuronal and satellite neuroglial cells, which are the 
most abundant glial cells in the peripheral nervous 
system[1]. The virus travels to the skin transaxonally 
through the sensory roots causing the characteristic 
vesicular rash within the corresponding dermatome(s)
[2].
  The clinical picture can involve any dermatome, but 
the preferred sites are the thoracic or lumbar nerve 
segments and the distribution area of the trigeminal 
nerve[3]. It may also spread to involve the nerve roots 
adjacent to the dorsal root ganglia causing a plexitis or 
neuritis. 
  The ability of this virus to spread and infect various 
neuronal cells explains the diversity of its clinical 
manifestations. Viral reactivation may occur reduced 
cell-mediated immunity to HZ occurs with aging, 
explaining the increased incidence in the elderly 
and from other causes such as tumors, human 
immunodeficiency virus (HIV) and immunosuppressant 
drugs. Diagnosis is usually clinical from typical 
unilateral dermatomal pain and rash[4].
  We want to indicate unusual localization of HZ on the 
acute myeloblastic leukemia child patient. 
Herpes zoster (HZ) is often associated with painful erythematous vesicular eruptions of the skin or 
mucous membranes. Approximately 10% to 30% of the population will suffer from HZ during their 
lifetime. HZ is infrequent in healthy children. However, diminished cellular immunity seems to 
increase risk of reactivation because incidence increases with age and in immunocompromised 
states. We report a 7-year-old girl with acute myeloblastic leukemia HZ infection on the right 
palmar, elbow and forearm region (C7, C8 and T1 dermatomes). We want to indicate unusual 
localization of HZ on the acute myeloblastic leukemia child patient. 
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2. Case report
  In this article, we report a case of HZ located on the 
right palmar, elbow and forearm region (C7, C8 and 
T1 dermatomes) in a child with acute myeloblastic 
leukemia (AML) because of unusual localization. A 
7-year-old girl followed with the diagnosis of AML 
M3 for 32 months was admitted with the complaints of 
swallow, burning sensation, grouped vesicles on an 
erythematous base, pain on the right palmar, elbow 
and forearm and fever for 2 days. On personal history, 
she suffered from chickenpox 3 years ago. She was 
administered AML M3 AIDA continuous protocol 
6-mercaptopurine 90 mg/(m2.d) and methotrexate 15 
mg/(m2.week). Now, she is on the 94th week before 
development of vesicular rashes. 
  On physical examination, vesicular rashes were noted 
the right on C7, C8 and T1 dermatomes (Figure 1). The 
reminder findings of physical examination were normal. 
Figure 1. Grouped vesicles with erythematous base on the right 
palmar, elbow and froearm region (C7, C8 and T1 dermatomes).
  Laboratory findings were as follows: Hemoglobin 
12 g/dL, white blood cell count 2 000/mm3, platelet 
count 29 000/mm3, sedimentation rate 40 mm/h and 
C-reactive protein 3.2 mg/dL. Anti-HIV and Varicella-
Zoster virus (VZV) immunoglobulin M were negative. 
Unfortunately, VZV immunoglobulin G could not be 
analyzed. Intravenous acyclovir (15 mg/kg 3 times daily) 
for 7 days and paracetamol (15 mg/kg 4 times daily per 
oral) were administrated on the 4th of treatment, her 
pain relieved and the vesicular lesions were faded. The 
patient was discharged on the 8th day of hospitalization 
in good health. 
3. Discussion
  HZ infection is usually associated with vesicular 
eruptions of the skin or mucous membranes. From birth 
to age 9 years, annual incidence is 0.74 cases per 1 
000 population in USA[2]. Usually a single, unilateral 
dermatome is involved[2]. HZ is more likely to occur 
in situations such as malignancy, steroid therapy, and 
old age when the immune system is depressed, thus 
allowing reactivation of the herpes virus[5]. HZ was seen 
only 2%-3% of patients with leukemia or after bone 
marrow transplantation[6]. Our patient was a child with 
acute myeloblastic leukemia. 
  The characteristic changes in infected cells are 
‘ballooning degeneration’  with the formation of 
intranuclear inclusion bodies and multinucleated giant 
cells. Viral particles within neurons and satellite cells 
in the sensory ganglia or in peripheral sensory nerves 
were demonstrated early in the disease via electron 
microscopy or fluorescent antibody staining[7]. 
  During primary infection, the etiological agent has the 
ability to infect the sensory nerves in mucocutaneous 
sites and then to become latent in the sensory-nerve 
ganglia[8]. In most patients, a painful eruption of 
grouped vesicles on an erythematous base develops 
within a sensory dermatome, usually on the trunk. 
In some cases, the face, neck, scalp or an extremity 
may be involved[8]. The cutaneous eruption typically 
involves a single dermatome and rarely crosses the 
midline.
  Trunk from T3 to L2 are most frequently affected; the 
thoracic region alone accounts for more than one-half 
of all reported cases, and lesions rarely occur distal 
to the elbows or knees[9]. In immunocompromised 
patients, particularly in those affected by cellular 
immunodeficiency, HZ can be clinically more severe, 
with atypical presentations at the immunosuppressed 
patient[10]. In accordance with the literature, the patient 
with AML of HZ, which was localized in C7, C8 and T1 
dermatomes, was an immunocompromised patient and 
she showed atypical presentation.
  The diagnosis of HZ is usually made based on 
unilateral pain in a defined area accompanied by 
a typical rash in the dermatomal distribution of 
a segmental nerve[4]. Antiviral agents have been 
shown to decrease the duration of HZ rash and the 
severity of pain associated with the rash. Antiviral 
agents inhibiting DNA polymerase such as acyclovir, 
valacyclovir and famciclovir should be used in HZ. 
   However, these agents are effective within 72 h 
after the onset of the rash if patients have severe or 
moderate pain or severe or moderate rash or they are 
immonocompromised or suffer from HZ ophtalmicus[10]. 
A paracetamol and weak opioid (codeine) compound 
is effective in many patients.  Stronger opioids 
(dihydrocodeine,  t ramadol ,  and morphine)  are 
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sometimes required[4]. In our patient, we initiated 
parenteral acyclovir, paracetamol and antiseptic 
solution (mixture with rivanol) 48 h after the appearance 
of HZ lesions and in the fourth of treatment, her pain 
relieved.
  In conclusion, our patient showed that lesions of 
HZ might be atypically localized on ulnar nerve in 
immunocompromised patients and acyclovir therapy 
was useful to relieve of the symptoms.       
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